TN2022000185A1 - Methods of treating splenomegaly - Google Patents

Methods of treating splenomegaly

Info

Publication number
TN2022000185A1
TN2022000185A1 TNP/2022/000185A TN2022000185A TN2022000185A1 TN 2022000185 A1 TN2022000185 A1 TN 2022000185A1 TN 2022000185 A TN2022000185 A TN 2022000185A TN 2022000185 A1 TN2022000185 A1 TN 2022000185A1
Authority
TN
Tunisia
Prior art keywords
methods
splenomegaly
treating
treating splenomegaly
therapeutic methods
Prior art date
Application number
TNP/2022/000185A
Other languages
English (en)
Inventor
Wayne Philip Rothbaum
Original Assignee
Telios Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma Inc filed Critical Telios Pharma Inc
Publication of TN2022000185A1 publication Critical patent/TN2022000185A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
TNP/2022/000185A 2020-01-08 2021-01-08 Methods of treating splenomegaly TN2022000185A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Publications (1)

Publication Number Publication Date
TN2022000185A1 true TN2022000185A1 (en) 2024-04-01

Family

ID=76788747

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP/2022/000185A TN2022000185A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Country Status (15)

Country Link
EP (2) EP3980069A4 (cg-RX-API-DMAC10.html)
JP (2) JP7771064B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220130151A (cg-RX-API-DMAC10.html)
CN (1) CN114423457A (cg-RX-API-DMAC10.html)
AU (1) AU2021205484A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022013646A2 (cg-RX-API-DMAC10.html)
CA (1) CA3164063A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022010592A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220374A (cg-RX-API-DMAC10.html)
IL (1) IL294582A (cg-RX-API-DMAC10.html)
JO (1) JOP20220168A1 (cg-RX-API-DMAC10.html)
MA (3) MA63848B1 (cg-RX-API-DMAC10.html)
MX (1) MX2022008490A (cg-RX-API-DMAC10.html)
TN (1) TN2022000185A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021142257A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12662484B2 (en) 2016-08-17 2026-06-23 Shenzhen Targetrx, Inc. Substituted piperidines as bruton's tyrosine kinase inhibitors
WO2021142257A1 (en) * 2020-01-08 2021-07-15 Telios Pharma, Inc. Methods of treating splenomegaly
US12697333B2 (en) 2020-01-08 2026-08-04 Telios Pharma, Inc. Methods of treating splenomegaly
WO2022266285A1 (en) * 2021-06-16 2022-12-22 Telios Pharma Inc. Treatment of symptoms associated with myeloproliferative neoplasms
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
JP2025527431A (ja) * 2022-08-25 2025-08-22 ビーワン メディシンズ ワン ゲーエムベーハー （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド及びシュウ酸を含む固体形態、その組成物及び使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
SMT202100674T1 (it) * 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
WO2016054491A1 (en) * 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3810590A1 (en) * 2018-06-19 2021-04-28 Merck Patent GmbH Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
CN109942835A (zh) * 2019-03-27 2019-06-28 广州楹鼎生物科技有限公司 一种催化分解木质纤维原料的方法
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
WO2021142257A1 (en) * 2020-01-08 2021-07-15 Telios Pharma, Inc. Methods of treating splenomegaly

Also Published As

Publication number Publication date
CR20220374A (es) 2023-01-25
AU2021205484A1 (en) 2022-08-18
WO2021142257A1 (en) 2021-07-15
EP4000624A1 (en) 2022-05-25
BR112022013646A2 (pt) 2022-10-04
JP7771064B2 (ja) 2025-11-17
CA3164063A1 (en) 2021-07-15
CO2022010592A2 (es) 2022-10-31
JP2023509968A (ja) 2023-03-10
MA57226A1 (fr) 2023-02-28
MX2022008490A (es) 2022-10-13
EP3980069A1 (en) 2022-04-13
MA69153A1 (fr) 2025-07-31
IL294582A (en) 2022-09-01
MA63848B1 (fr) 2024-10-31
JP2026027353A (ja) 2026-02-18
EP3980069A4 (en) 2022-08-17
KR20220130151A (ko) 2022-09-26
CN114423457A (zh) 2022-04-29
MA57226B1 (fr) 2023-06-28
JOP20220168A1 (ar) 2023-01-30
MA63848A1 (fr) 2024-04-30

Similar Documents

Publication Publication Date Title
JOP20220168A1 (ar) طرق علاج الطحال
MX2022004983A (es) Composiciones de profarmaco y metodos de tratamiento.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
PH12023552741A1 (en) Psilocybin Compositions, Methods Of Making And Methods Of Using The Same
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2020011817A (es) Metodos para tratar el linfoma.
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
MX2025003515A (es) Moduladores de akt1
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
MX2023006419A (es) Compuestos polipéptidos modificados con lactama.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2017002825A (es) Tratamientos medicos a base de anamorelina.
PH12021551805A1 (en) Treatment of skin lesions and pruritus in prurigo nodularis patients
PH12020551820A1 (en) Methods of treating cancer
MX2025008834A (es) Proteinas de fusion anti-pd-1/il-2, composiciones farmaceuticas y aplicaciones terapeuticas
MX2026002367A (es) Composiciones de copolimero de bloque sensibles al ph, micelas, y metodos de uso
MX2023005156A (es) Composiciones terapeuticas sensibles al ph.
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.
CR20220071A (es) Composiciones farmacéuticas y métodos para tratar o prevenir la atrofia muscular espinal